

1 **Deep sequencing of DNA from urine of kidney allograft recipients to estimate the donor-**  
2 **specific DNA fraction**

3  
4  
5 Aziz Belkadi<sup>1</sup>, Gaurav Thareja<sup>1</sup>, Darshana Dadhania<sup>2,3</sup>, John R. Lee<sup>2,3</sup>, Thangamani  
6 Muthukumar<sup>2,3</sup>, Catherine Snopkowski<sup>3</sup>, Carol Li<sup>3</sup>, Anna Halama<sup>1</sup>, Sara Abdelkader<sup>1</sup>, Yasmin  
7 Mahmoud<sup>1</sup>, Joel Malek<sup>1</sup>, Manikkam Suthanthiran<sup>2</sup>, Karsten Suhre<sup>1,\*</sup>  
8  
9

10 <sup>1</sup> Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City,  
11 Doha, Qatar.

12 <sup>2</sup> Department of Transplantation Medicine, New-York Presbyterian Hospital-Weill Cornell  
13 Medicine, New York, NY

14 <sup>3</sup> Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medical  
15 College, New York, USA.

16  
17 \* Corresponding author

18 E-mail: [kas2049@qatar-med.cornell.edu](mailto:kas2049@qatar-med.cornell.edu)  
19

## 20 **Abstract**

21 Renal transplantation is the method of choice for patients with end stage kidney failure. But  
22 transplanted allograft could be affected by viral and bacterial infections and immune rejections.  
23 The standard test for the diagnosis of acute pathologies in kidney transplants is the renal biopsy.  
24 However, noninvasive tests would be desirable. Various methods using different techniques have  
25 been developed by the transplantation community. But these methods expect improvements. We  
26 present here a cost-effective method based on estimating donor-specific DNA fraction in recipient  
27 urine based on sequencing of recipient urine DNA only. We hypothesized that in the no-pathology  
28 stage, the largest tissue types present in recipient urine are donor kidney cells and in case of  
29 rejection, a larger number of recipient immune cells would be observed. Extensive in-silico  
30 simulation was used to tune the sequencing parameters: number of variants and depth of coverage.  
31 Sequencing of DNA mixture from 2 healthy individuals showed the method high prediction  
32 accuracy (maximum error < 0.04). We then demonstrated the insignificant impact of familial  
33 relationship and ethnicity using an in-house and public database. Lastly, we performed recipient  
34 deep urine DNA sequencing in 32 samples representing two pathology groups: acute rejection  
35 (AR, 12 samples) and acute tubular injury (ATI, 11 samples) and 9 samples with no pathology.  
36 We found a significant association between the donor-specific DNA fraction in the two pathology  
37 groups compared to no pathology ( $P = 0.0064$  for AR and  $P = 0.026$  for ATI). We conclude that  
38 deep DNA sequencing of recipient urine offers a noninvasive means of diagnosing and  
39 prognosticating acute pathologies in the human kidney allograft.

40

## 41 **Introduction**

42 In 1933 surgeon Yurii Voronoy from Ukraine achieved the first human kidney transplantation [1].  
43 Kidney transplantation is the final treatment option for patients with end-stage renal failure after  
44 dialysis. Today, renal transplantation plays an important role in clinical medicine and has become  
45 a relatively safe intervention. However, various pathologies can still affect the transplanted organ,  
46 including infections, disease recurrence and immune rejections. These rejections can be related to  
47 a range of donor- and recipient-specific factor risks [2,3]. Acute renal rejection affects 10 to 20%  
48 of transplants within three months after transplantation and chronic rejections occur in 4% of  
49 kidney transplants [3–5].

50 To diagnose allograft rejection, tissue biopsies are considered as the gold-standard method for  
51 detecting acute and chronic immune injury, as well as other pathologies associated that may  
52 eventually lead to allograft loss. However, biopsies are invasive, costly, in rare cases they can lead  
53 to organ loss, while the readout can potentially be erroneous if a non-affected part of the kidney is  
54 sampled by chance. Therefore, proceeding with biopsies in patients of low immunological risk is  
55 sometimes criticized [6]. There is hence a strong need for non-invasive assays to detect injury in  
56 transplanted kidneys. Several studies to develop suitable biomarkers for allograft rejection have  
57 been conducted. These studies include the quantification of specific messenger RNAs in urine [7],  
58 large-scale transcriptomics analyses of peripheral blood [8], proteomics analyses of biopsies [9]  
59 and urine [10,11], and metabolomics [12] and RNA sequencing [13] of urine pellet or supernatant.  
60 Nevertheless, all non-invasive methods developed to date still have important caveats and require  
61 further improvement.

62 The presence of donor-specific DNA in blood was first reported in women who had a kidney and  
63 a liver transplant [14]. The measurement of cell-free donor-specific DNA in blood for a differential  
64 diagnosis of kidney injury has been suggested recently [15–17]. These studies focused on females  
65 who received a kidney from male donors by identifying the presence of DNA coding for the testis  
66 specific protein *Y-linked 1* (TSPY1) or the sex-determining region of the Y chromosome using  
67 quantitative polymerase chain reaction. With the improvement of next generation sequencing  
68 technologies, whole genome sequencing (WGS) [18,19] and targeted sequencing [20] were used  
69 for measuring donor-specific DNA for solid organ transplant rejection. However, these studies  
70 focused on heart transplants and measured cell-free donor-specific DNA in blood plasma. More

71 importantly, these methods require the sequencing of both donor and receptor DNA which is more  
72 costly.

73 An algorithm for measuring donor-specific DNA in plasma of organ transplants without requiring  
74 donor or recipient genotyping was implemented by Gordon et al [21]. But this algorithm made the  
75 assumption that donor fraction is < 14%. More recently, Grskovic *et al.* used sequencing of 266  
76 single nucleotide variants (SNVs) that discriminate best between two unrelated individuals to  
77 count reference and alternative allele frequency for estimating the donor-derived cell-free DNA  
78 fraction [22]. This method showed a high correlation between cell-free donor specific DNA levels  
79 in recipient blood and active rejection of the kidney allografts [23]. However, this method does  
80 not account for potential sequencing errors and requires *a priori* knowledge of the familial  
81 relationship between donor and recipient. Finally, a statistical method combining SNV array  
82 genotyping of donor and recipient before transplantation with recipient DNA sequencing was used  
83 to estimate recipient-derived DNA fraction in heart and lung transplants [24]. Nonetheless, this  
84 method requires SNV genotyping of donor and recipient DNA before transplantation. Most  
85 importantly, all of the previous study focused on DNA extract from blood.

86 The presence of donor-specific DNA in urine of kidney allograft recipients has been reported [25].  
87 We have recently conducted a study based on RNA sequencing of tissue biopsies from kidney  
88 allograft transplants and found a correlation between the ratio of heterozygous to homozygous  
89 SNVs with the rejection phenotype [26]. Moreover, we have shown in another study that DNA  
90 methylation could be used to accurately estimate the tissue type composition in recipient urine  
91 samples. We found that the largest tissue types present in recipient urine were kidney cells and  
92 neutrophils and that donor-specific DNA fraction correlates with the kidney derived cell fraction  
93 [27]. However, we restricted the analysis on kidney recipients with urinary tract infection and BK-  
94 virus nephropathy only. Most recently, we have identified different gene signatures and pathways  
95 associated with two different type of kidney rejection using RNA-seq on transplant urine: acute T  
96 cell-mediated rejection and antibody-mediated rejection [13]. Deconvolution analysis showed a  
97 higher enrichment of immune cells in rejection stage comparing to no-rejection.

98 Based on the idea that the fraction of donor-specific DNA can be determined using DNA  
99 sequencing, we here hypothesize that the recipient-specific DNA fraction in urine correlates with  
100 the level of active rejection in the kidney allograft, assuming that recipient-specific DNA  
101 originates mostly from tissue-invading immune cells while donor-specific DNA stems from the


102 allograft [28]. Inspired by methods to estimate DNA contamination in sequencing projects [29,30],  
103 we present a cost-effective method to determine the fraction of donor-specific DNA (denoted  $\alpha$   
104 hereafter) in urine by sequencing targeted regions. We estimate the dependence of the precision of  
105 this measure on sequencing depth and length of the targeted region. Most importantly, no prior  
106 knowledge of donor and recipient relation is required. To the best of our knowledge, this is the  
107 first method for estimating donor-specific DNA fraction in DNA mixture extracted from recipient  
108 urine. Our method provides an easy way to determine the donor-specific DNA fraction regardless  
109 of donor and recipient gender. We evaluate its applicability for the detection of kidney transplant  
110 rejection. Future applications could be routine tests of urine samples as a reference to adjust and  
111 optimize the dosage of immune suppressants in kidney transplant patients.

## 112 **Results**

### 113 **In silico simulation of donor-recipient DNA mixtures**

114 To determine the optimal sequencing parameters, we use numerical simulations. The simulation  
115 process is based on generating two different SNV-sets, merge the two sets with a predefined  
116 proportion of each set;  $\alpha$  from set 1 and  $(1-\alpha)$  from set 2, and then apply a likelihood function  
117 (Methods) to estimate this proportion (*observed*  $\alpha$ ). Two major parameters affect the estimation of  
118 the *observed*  $\alpha$ : the number of sequenced SNVs ( $N$ ) and the depth of sequencing coverage ( $M$ ).  
119 For a range of parameters  $N=\{10, 50, 100, 500, 1,000\}$  and  $M=\{10, 50, 100, 500, 1,000, 5,000,$   
120  $10,000\}$  and varying  $\alpha$  from 0 to 0.5 in steps of 0.01, we repeated the simulation process for each  
121  $N \times M \times \alpha$  combination 1,000 times to obtain an empirical distribution of *observed*  $\alpha$  (Fig S1).

122 We computed the maximum error ( $\epsilon$ ) for each combination  $N \times M$  over all tested  $\alpha$ .  $\epsilon$  ranges  
123 between 0 (best case where *observed*  $\alpha =$  tested  $\alpha$ ) and 0.5 (worst case where tested  $\alpha = 0.5$  and  
124 *observed*  $\alpha = 0$  or tested  $\alpha = 0$  and *observed*  $\alpha = 0.5$ ) (Fig 1). As expected, our simulations show  
125 that increasing both  $N$  and  $M$  improves the *observed*  $\alpha$  estimation accuracy. Moreover, the  
126 estimation of the *observed*  $\alpha$  is unstable when using a small number of SNVs ( $N < 100$ ) or low  
127 coverage ( $M < 500$ ). The prediction accuracy stabilizes above  $N > 500$  and  $M > 1,000$ .



128  
129 **Fig 1. Maximum error for detecting the DNA fraction  $\alpha$  in a simulated DNA sequencing**  
130 **experiment varying sequencing depth and number of SNVs. Maximum absolute (A) and**  
131 **relative (B) errors are represented. A total of 35 scenarios combining five different numbers of**  
132 **SNVs  $N = \{10, 50, 100, 500, 1,000\}$  and seven depth of coverage  $M = \{10, 50, 100, 500, 1,000,$**   
133 **5,000, 10,000\} were simulated (Fig S1). Represented here are maximum error observed in 1,000**  
134 **simulations for every tested  $\alpha$  ranging from 0 to 0.5 in steps of 0.01.**  
135

### 136 **Experimental estimation of $\alpha$ using a controlled mixture of urine from two individuals**


137 To assess the accuracy of detecting *observed*  $\alpha$  in a mixture of two real human urine samples, we  
138 performed a targeted sequencing of urine DNA from two healthy individuals originated from  
139 different populations; S1 a 35 years old healthy European woman and S2 a 34 years old healthy  
140 Arab woman. A total of 1,850 exonic regions from a panel targeting 93 genes known to be  
141 associated with risk of breast cancer were sequenced. These sequenced genomic regions cover  
142 370,942 base pairs across 22 chromosomes (Table S1). A total of 51,893 bi-allelic SNVs falling  
143 in these genomic regions were present in the Exome Aggregation Consortium (ExAC) [31]. As  
144 the method works on bi-allelic SNV with different genotypes between donor and recipient, we  
145 computed for each SNV the probability of having different genotypes for two individuals (Table  
146 S1). Only 437 SNVs have a probability of having different genotypes for two individuals higher  
147 than 10%.

148 As a measure of quality control, we first checked the balance of reference and alternative alleles  
149 in heterozygous calls. The alternative allele frequency is expected to be around 50% in  
150 heterozygous genotypes. However, we observed the presence of SNVs with skewed alternative  
151 allele frequencies (Fig S2). We noticed the recurrence of such unbalance in every replicate of both  
152 samples (Fig S3 for examples). We investigated whether the amplification-based strategies for  
153 DNA target enrichment affect the allele dropout causing the skewed alternative allele distribution.  
154 We found that the SNVs with a skewed distribution all fall into the primer sequence regions. We  
155 therefore filtered out SNVs falling into these regions and kept the 1,000 most common SNVs in  
156 the general population. These 1,000 SNVs will be used as a SNVs panel for detecting DNA fraction  
157 in a combination of two DNA sources (*observed  $\alpha$* ) in the rest of the study. The alternative allele  
158 frequency was balanced in these 1,000 SNVs (Fig S4). Moreover, the maximum error of estimating  
159 the *observed  $\alpha$*  based on these 1,000 SNVs in all replicates was  $< 0.0034$  (mean error =  $0.0028 \pm$   
160  $0.00037$ ).

161 We then mixed 90 % DNA from S1 and 10% DNA from S2 in three replicates. For each replicate,  
162 targeted DNA sequencing was performed and the *observed  $\alpha$*  was estimated. The preparation of  
163 the mixture was based on total DNA content in the samples. However, the presence of bacterial  
164 DNA in urine samples can strongly skew the estimation of human DNA concentration  
165 measurement [32]. We assessed the actual DNA concentration of S1 and S2 in urine by considering  
166 the mean *observed  $\alpha$*  over the three replicates to 0.053. This indicates that S1 DNA concentration  
167 is ~19 times lower than S2 DNA concentration. Considering the estimated S1 and S2 DNA  
168 concentration, the maximum error of the *observed  $\alpha$*  was  $< 3.5\%$  in the three replicates (Fig 2).

169 We extended the analysis to two levels of DNA mixture scenarios: (i) 70% DNA from S1 and 30%  
170 DNA from S2, (ii) 50% DNA from S1 and 50% DNA from S2. Each scenario was replicated three  
171 times and targeted DNA sequencing was performed for each replicate. The *observed  $\alpha$*  was similar  
172 in the three replicates of all three scenarios (scenario i: mean *observed  $\alpha$*  =  $0.11 \pm 0.036$ , scenario  
173 ii: mean *observed  $\alpha$*  =  $0.032 \pm 0.00048$ ). Considering the estimated S1 and S2 DNA concentration,  
174 the maximum error of the *observed  $\alpha$*  was  $< 3.8\%$  in all replicates of both scenarios ( $0.037$  in  
175 scenario (i) and  $0.018$  in scenario (ii)) (Fig 2).

176



177  
 178 **Fig 2. Estimation of DNA fraction (Alpha) in a combination of two healthy DNA sources.**  
 179 Five scenarios of DNA mixtures and three replicates for each scenario were performed. From left  
 180 to right: 100% from individual S1 and 0 % from individual S2, 0% from individual S1 and 100%  
 181 from individual 2, 50% from individual 1 and 50% from individual 2, 70% from individual S1 and  
 182 30% from individual S2, 90% from individual S1 and 10% from individual S2. The estimated  
 183 fractions (*estimated*  $\alpha$ ) are represented by black dots. The expected fractions when DNA  
 184 concentration in individual S1 was 19 times lower than DNA concentration in individual S2 are  
 185 represented by red dots. The expected fractions before correction for DNA concentration are  
 186 represented by blue dots.  
 187 **Simulation of the effect of family relationship and ethnicity on the estimation of  $\alpha$**


188 The most challenging scenario is that of one sibling donating a kidney to another, as they share  
 189 50% of their genome. The extreme case of mono-zygotic twins, where both genomes are identical,  
 190 can of course not be addressed with our method. To numerically explore this "worst case" scenario,  
 191 we used whole genome sequencing data from 91 siblings [33] and then generated 100  
 192 combinations of every two siblings. Self-reported relationship was confirmed using identity by  
 193 state (Fig S5). For each pair of siblings, we simulated donor and recipient DNA sequences by



194 varying  $\alpha$  from 0 to 0.5 in steps of 0.01 and resampling the mean coverage at 5,000 reads. The  
 195 maximum absolute error was observed when the expected  $\alpha = 0.07$ : *observed*  $\alpha = 0.034$  (Fig 3).  
 196

### 197 **Simulation of the effect of population origin on the estimation of $\alpha$**

198 As per comparison to siblings, we assessed the effect of donor and recipient ethnicity on our  
 199 method. We applied our method on simulated pairs of individuals belonging to the same and to  
 200 different populations of the 1,000 genomes project [34]: Africans, Americans, east Asians,  
 201 Europeans and south Asians. The absolute error was  $< 0.04$  in all scenarios (Fig 3). As expected,  
 202 the absolute error was lower when the two DNA sources belong to different populations (mean  
 203 maximum absolute error =  $0.018 \pm 0.005$ ) than when they belong to the same population (mean  
 204 maximum absolute error =  $0.022 \pm 0.007$ ). Additionally, the maximum relative error was  
 205 comparable in all scenarios together (mean maximum relative error =  $0.836 \pm 0.137$ ) compared to  
 206 when the two DNA sources belong to the same (mean maximum relative error =  $0.764 \pm 0.207$ ) or  
 207 different populations (mean maximum relative error =  $0.856 \pm 0.077$ ). These results confirm the  
 208 power of the method for detecting the DNA fraction in a combination of two DNA sources  
 209 independently of the familial relationship or their ethnicity.



210  
 211 **Fig 3. Effect on family relationship and ethnicity on detecting DNA fraction in a combination**  
 212 **of two DNA sources.** Each dot represents in A) the maximum absolute error and in B) the  
 213 maximum relative error for each expected ( $\alpha$ ) from 0 to 0.5 in steps of 0.01 over 100 pairs of  
 214 siblings (red), 100 pairs of individuals belonging to the same population (green) and 100 pairs of

215 individuals belonging to different populations (blue). Afr = Africans. Amr = Americans. Eas =  
216 East Asians. Eur = Europeans. Sas = South Asians.  
217

### 218 **Application to urine samples from clinical kidney allograft patients**

219 To test our method in a real-case scenario, we used DNA extracted from 32 urine samples of 26  
220 kidney allograft recipients collected at the time a diagnostic biopsy was performed and divided the  
221 sample into three groups based on their Banff classification: “Acute Tubular Injury” (ATI, N =  
222 12), “Acute Rejection” (AR, N = 11) and “No Observed Pathology” (N = 9) (Table 1). DNA was  
223 extracted from urine and deep targeted sequencing was performed for the 32 samples. Reflecting  
224 the effect of depth of coverage on the accuracy of detecting *observed  $\alpha$*  in simulated data, we set  
225 the mean depth of coverage to  $\sim 14,000$  reads. After read alignment we applied our method to  
226 estimate the donor to total DNA fraction (Fig 4).


227 The difference of *observed  $\alpha$*  between the diagnosis phenotypes was statistically significant ( $P =$   
228 0.035, Kruskal-Wallis test). We observed a significant difference when comparing the two  
229 transplant kidney pathologies ATI and AR to the No Pathology group ( $P = 0.0064$  and  $P = 0.026$ ,  
230 Dunn’s test for ATI vs no pathology and AR vs no pathology, respectively). However, no  
231 significant difference was observed in *observed  $\alpha$*  when comparing the two pathologies ATI to AR  
232 ( $P = 0.31$ , Dunn’s test).  
233

Recipient Characteristics	Patient Total (N=26)	Patients with AR (N=8)	Patients with ATI (N=10)	Patients with No Pathology (N=8)
Number of Biopsy Associated Urine Specimens	32	12	11	9
Age, years				
Mean (SD)	45.5 (14)	46.1 (19)	43.8 (14)	47.1 (8)
Median	43	43	40	49
Min, Max	25, 80	25, 80	29, 74	34, 59
Gender, N (%)				
Male	40 (100%)	40 (100%)	40 (100%)	40 (100%)
Race, N (%)				
White	8 (31%)	3 (38%)	3 (30%)	2 (25%)
Black	11 (42%)	4 (50%)	3 (30%)	4 (50%)
Hispanic	3 (11%)	1 (12%)	0 (0%)	2 (25%)
Asian	2 (8%)	0 (0%)	2 (20%)	0 (0%)
Mixed	2 (8%)	0 (0%)	2 (20%)	0 (0%)
Cause of ESRD, N (%)				
Diabetes	4 (15%)	1 (13%)	1 (10%)	2 (25%)
Hypertension	11 (42%)	3 (37%)	5 (50%)	3 (50%)
Glomerulonephritis	6 (23%)	3 (37%)	1 (10%)	2 (25%)
Polycystic Kidney Disease	3 (12%)	0 (0%)	2 (20%)	1 (11%)
Other	2 (8%)	1 (13%)	1 (10%)	0 (0%)
Prior Transplant History, N (%)	2 (8%)	1 (13%)	1 (10%)	0 (0%)
Donor Source, N (%)				
Living	17 (65%)	4 (50%)	7 (70%)	6 (75%)
Deceased	9 (35%)	4 (50%)	3 (30%)	2 (25%)
Induction Therapy, N (%)				
Antithymocyte globulin	23 (88%)	5 (62%)	10 (100%)	8 (100%)
IL-2 Receptor Antibody	3 (12%)	3 (38%)	0 (0%)	0 (0%)
Steroid Maintenance Therapy, N (%)	10 (38%)	4 (50%)	2 (20%)	4 (50%)

Post-Transplant Month, mean (SD)	8.26 (12.32)	9.79 (11.05)	1.56 (1.64)	15.10 (17.20)
Biopsy Creatinine	3.1 (2.4)	2.9 (1.9)	4.4 (2.9)	1.6 (0.25)
One Year Post Biopsy Creatinine	2.2 (1.7)	2.9 (2.9)	2.0 (0.6)	1.8 (0.7)

234

235



236

237 **Fig 4. Donor to total DNA fraction in 32 real kidney allograft recipient urines.** Box plots and  
 238 individual data points of the estimated fraction (*observed*  $\alpha$ ) are estimated from deep urine DNA  
 239 targeted sequencing. AR: Acute Rejection. ATI: Acute Tubular Injury. A statistically difference  
 240 was observed between all the diagnosis phenotypes ( $P = 0.035$ , Kruskal-Wallis test). By Dunn's  
 241 test, difference in *observed*  $\alpha$  between the two pathologies and no pathology group was statistically  
 242 significant: ATI vs no-pathology:  $P = 0.0064$  and AR vs no-pathology:  $P = 0.026$ . Pathologies  
 243 pairwise comparison was not statistically significant ( $P > .05$ ).

244

#### 245 Inference of donor and recipient ethnic origin

246 In the absence of donor and recipient genomes, it is impossible to determine whether the *observed*  
 247  $\alpha$  represents the donor or the recipient fraction of the total DNA. However, in cases were recipient  
 248 and donor gender or ethnicity differ, this issue can be addressed. The urine DNA sequencing we  
 249 performed here did not target genomic regions of the Y chromosome. Thus, detecting recipient

250 and donor gender cannot be carried out using the actual data, but could be easily amended in future  
251 sequencing panels.

252 To predict donor and recipient ethnicity, an estimation of both recipient and donor  
253 genotypes is needed. For each of 1,000 SNVs, we computed the fraction of the alternative to total  
254 alleles. We then used the *observed*  $\alpha$  to compute the nine expected fractions of the alternative allele  
255 (Table 2). We then used a cost function to estimate donor and recipient genotypes that minimizes  
256 the difference between the nine expected fractions and the observed fraction of the alternative to  
257 total alleles. Based on these estimated genotypes, we applied a supervised classification method to  
258 predict the recipient and the donor ethnicity as following: as donor-specific DNA fraction has been  
259 shown to be higher in the no-pathology group [28], we supposed the *observed*  $\alpha$  to represent the  
260 donor-to-total DNA fraction and computed the probability of donor and recipient for belonging to  
261 one of the three populations: African, East Asian and European (see Methods). Both donor and  
262 recipient are assigned to the population showing the highest probability and then compared to the  
263 self-reported ethnicity. Seven recipients and eight donors were excluded from the prediction  
264 because they belong to a mixed self-reported population or the *observed*  $\alpha$  was  $\sim 0$  so the prediction  
265 of donor genotypes was impossible. The prediction was inconclusive (Probability of prediction  $<$   
266 70%) for 5 recipients and 8 donors. In 16 over 20 recipients (80%) and 15 over 16 donors (94%),  
267 the probability of prediction was higher than 70%. However, only one AR sample and one ATI  
268 sample have donor and recipient ethnicity mismatch for whom the prediction was conclusive. In  
269 these two samples (European donor and African recipient for both samples), the prediction was in  
270 agreement with the self-reported ethnicity. Hence, due to the small number of self-reported  
271 ethnicity mismatches, it is impossible to confirm whether the *observed*  $\alpha$  represents the donor or  
272 the recipient DNA fraction (as *observed*  $\alpha < 0.5$  by definition).

273

274 **Table 2. Expected fraction of the alternative to total alleles (reference + alternative) as a**  
275 **function of *observed*  $\alpha$ .**

$g_i^R$	$g_i^D$	$exp_i$
0	0	0
0	1	$\alpha/2$
0	2	$\alpha$
1	0	$1 - \alpha/2$
1	1	$1/2$

1	2	$1 + \alpha/2$
2	0	$1 - \alpha$
2	1	$2 - \alpha/2$
2	2	1

276

## 277 **Discussion**

278 Different omics technologies, including mRNA measurement by PCR [7], metabolomics [12] and  
279 RNA-sequencing [13] have been applied by our group and others to identify non-invasive  
280 biomarkers for kidney allograft rejection. Here, we present a new approach based on targeted deep-  
281 sequencing of DNA obtained from urine samples. We extended methods originally used for the  
282 assessment of DNA contamination to estimate the fraction of recipient DNA in a two-sources  
283 mixed DNA sample [29,30]. We used in silico simulations to obtain a suitable parameter range for  
284 the method to be sufficiently accurate in estimating the fraction of a two-sources DNA mixture.  
285 We then experimentally evaluated the accuracy of the estimation method using controlled mixtures  
286 of two DNA sources. Allele drop-out occurs in amplification-based target enrichment when a  
287 variant is located in a primer region and prevents primer hybridization, leading to failed  
288 amplification and allele bias [35]. Our method overcomes these unexpected artefacts due to DNA  
289 sequencing. Other algorithm for estimating the donor-specific DNA fraction requires the donor  
290 and recipient relationship information [22]. Here, we found that ethnicity and familial relationship  
291 between donor and recipient appear to have a lower impact as compared to previously presented  
292 methods

293 We tested our method on clinical samples from patients with and without kidney rejection  
294 events. We compared the  $\alpha$  value obtained from urine DNA sequencing reads of kidney allograft  
295 recipients with kidney injury associated with AR and ATI. The alpha value was significantly  
296 different in patients with AR and ATI compared to those without kidney pathology. The  
297 calculation of alpha is based on the assumption that the DNA isolated from the urine is derived  
298 from the transplanted kidney where both the recipient and the donor DNA are present: Recipient  
299 DNA from the infiltrating immune cells and the donor DNA from the kidney parenchymal cells.  
300 Indeed, we have recently shown in kidney recipients with donor-recipient gender mismatch by  
301 counting Y chromosome-derived cell free DNA that donor-specific DNA fraction was lower in  
302 recipient with UTI as comparing to the no UTI and higher in recipients with BKVN comparing to

303 the no BKVN [28]. Thus, our approach might be considered as a potential new diagnostic signature  
 304 measured in urine specimens.

305 We were not able to assert whether the recipient urine DNA is mostly donor's or  
 306 recipient's. Studies have shown that both AR and ATI are associated with allograft damage  
 307 indicating that there will be some donor DNA in the urine. But AR is also associated with recipient  
 308 immune cell infiltration while ATI is not [36]. Thus, the fraction of recipient to donor cells in the  
 309 urine should be higher for AR compared to ATI and perhaps should be just the opposite with AR  
 310 showing a fraction of donor to recipient of much lower than 0.5 and ATI showing a fraction of  
 311 donor to recipient of much greater than 0.5. To address this, a future complementary analysis on a  
 312 bigger sample having donor and recipient ethnicity and/or gender mismatches will be worthwhile.

## 313 **Methods**

### 314 **Algorithm**

315 The algorithm is inspired by the contamination estimation in DNA sequencing method [29,30].  
 316 We hypothesize that recipient urine contains a mix of recipient and donor DNA. Let  $N$  be the  
 317 number of bi-allelic SNVs sequenced from recipient urine DNA and each SNV  $i$  is covered by  $M_i$   
 318 reads. Let  $g_i^R$  and  $g_i^D$  be the genotype of recipient and donor at the SNV  $i$ , respectively. Both  $g_i^R$   
 319 and  $g_i^D$  are unknown. Limiting the analysis on bi-allelic SNVs only leads to three possible  
 320 genotypes for recipient and donor at each SNV  $i$ :  $g_i^R$  ( $g_i^D$ ) =  $\{0, 1, 2\}$  where 0 = homozygous wild  
 321 type, 1 = heterozygous and 2 = homozygous for the alternative allele. The likelihood of the donor-  
 322 specific DNA fraction ( $\alpha$ ) will be:

$$\begin{aligned}
 323 \quad L(\alpha) = & \prod_{i=1}^N \sum_{g_i^R} \sum_{g_i^D} \left\{ \prod_{j=1}^{M_i} \sum_{e_{ij}} \left( (1 - \alpha) P(b_{ij} | g_i^R, e_{ij}) \right. \right. \\
 324 \quad & \left. \left. + \alpha P(b_{ij} | g_i^D, e_{ij}) \right) P(e_{ij}) \right\} P(g_i^R) P(g_i^D)
 \end{aligned}$$

325 Where  $b_{ij}$  represents the read  $j$  covering the SNV  $i$  and  $e_{ij}$  represents the sequencing error of SNV  
 326  $i$  at the read  $j$ :  $P(e_{ij} = 1) = 10^{-Q_{ij}/10}$  and  $P(e_{ij} = 0) = 1 - P(e_{ij} = 1)$  and  $Q_{ij}$  represents the minimum  
 327 between the base quality of the read  $j$  at the position of the variant  $i$  and the mapping quality of the  
 328 read  $j$ . The probability of  $b_{ij}$  conditioned to the recipient (donor) genotype  $g_i^R$  ( $g_i^D$ ) and the  
 329 sequencing error  $e_{ij}$  is described in Table 3. Finally, we used the simulated annealing approach

330 together with a grid search to find  $\alpha$  that maximizes the likelihood function [37]. The method was  
 331 implemented in a Python script.

332

333 **Table 3. The probability of read  $b_{ij}$  carrying the reference (a), alternative (A) or a different**  
 334 **allele (e) conditioned to the recipient (donor) genotype  $g_i^R$  ( $g_i^D$ ) and the sequencing error  $e_{ij}$ .**

	$g_i^R (g_i^D) = 0$		$g_i^R (g_i^D) = 1$		$g_i^R (g_i^D) = 2$	
	$e_{ij} = 0$	$e_{ij} = 1$	$e_{ij} = 0$	$e_{ij} = 1$	$e_{ij} = 0$	$e_{ij} = 1$
$P(b_{ij} = a)$	1	0	1/2	1/6	0	1/3
$P(b_{ij} = A)$	0	1/3	1/2	1/6	1	0
$P(b_{ij} = e)$	0	2/3	0	2/3	0	2/3

335

336 As the likelihood function for estimating  $\alpha$  requires a balance in alternative/reference allele  
 337 distribution in heterozygous calls for both recipient  $g_i^R$  and donor  $g_i^D$  genotypes, very deep  
 338 recipient urine DNA sequencing will provide this allele balance (Table 4).

339

340 **Table 4. The probability and the 99% interval confidence of a perfect allele balance in a**  
 341 **heterozygous call as a function of depth of coverage  $M$ . A total of 10,000 simulations were**  
 342 **performed for each proposed  $M$ .**

$M$	$P(\text{alt}/(\text{ref}+\text{alt}) = 0.5)$	99% confidence interval
10	0.24	[0.10, 0.90]
50	0.11	[0.34, 0.66]
100	0.08	[0.39, 0.62]
500	0.18	[0.45, 0.55]
1,000	0.27	[0.46, 0.54]
5,000	0.53	[0.48, 0.52]
10,000	0.69	[0.49, 0.51]

343

344 **Simulated SNVs based on general population structure**



345 To assess the effect of number of SNVs ( $N$ ) and mean depth of coverage ( $M$ ) on the allele balance  
346 and thus the prediction accuracy of the likelihood function, we simulated 2 independent SNV-sets  
347 each set containing  $N$  common SNVs (minor allele frequency  $\geq 5\%$ ) and is covered on average by  
348  $M$  reads. We varied  $N$  and  $M$  in 35 scenarios where  $N=\{10, 50, 100, 500$  and  $1,000\}$  and  $M=\{10,$   
349  $50, 100, 500, 1,000, 5,000$  and  $10,000\}$ . We merged  $\alpha$  reads from set1 and  $1-\alpha$  from set2 randomly  
350 generating a combined SNV-set and applied the likelihood function on the combined SNV-set to  
351 estimate the *observed*  $\alpha$ . Because  $L(\alpha) = L(1-\alpha)$ , we restrict  $0 \leq \alpha \leq 0.5$  in steps of 0.01 generating  
352 51 scenarios. A thousand replicates for each scenario and for each  $\alpha$  were performed to obtain an  
353 empirical distribution.

### 354 **Sequencing of urine DNA from a pair of healthy individuals**

355 We extracted DNA from urine of two healthy individuals; S1, a 30 years old European woman and  
356 S2 a 30 years old Arab woman using the Qiagen® Allprep Mini Kit. extraction kit. The DNA  
357 concentration was similar for the two individuals: 35ng/ $\mu$ l. We mixed DNA from S1 and S2 to  
358 achieve 5 scenarios: i) 100% from S1, ii) 100% from S2, iii) 90% from S1 and 10% from S2, iv)  
359 70% from S1 and 30% from S2, v) 50% from S1 and 50% from S2 and each scenario was replicated  
360 three times. We performed deep targeted DNA sequencing on each replicate. GeneReadDNA Seq  
361 Targeted Pannels V2; Human Breast Cancer Panel (Qiagen, USA) was used to perform target  
362 enrichment by multiplex PCR. The breast cancer panel consists of four primer pools yielding 2,915  
363 amplicons. Briefly, 40ng of each gDNAs was amplified using PCR reagents with 4 primer pool  
364 mixes following the manufacturer's protocol. After the completion of the 4 PCR reactions, the 4  
365 products were combined and the enriched DNA was purified using Agencourt AMPure XP beads  
366 (Beckman Coulter, USA). The concentration and the size of the purified amplicons were  
367 determined using Qubit 2.0 Fluorometer dsDNA BR assay kit (LifeTechnologies, USA) and  
368 Agilent BioAnalyzer 2100 High-Sensitivity DNA kit (Agilent Technologies, USA). A total  
369 amount of 80-160 ng of purified enriched DNA was used as template to generate NGS libraries.  
370 The NGS libraries were prepared using NEBNext Ultra II DNA Library Prep Kit (New England  
371 Biolabs, USA) and NEXTflex DNA Barcodes (Bio Scientific, USA). All library preparation steps  
372 were performed according to the manufacturer's protocol. The size and quality of the final libraries  
373 were analyzed using Agilent BioAnalyzer 2100 with 1000 DNA kit (Agilent Technologies, USA).  
374 The quantified libraries were then normalized, pooled, and spiked with 5% PhiX control library

375 (Illumina, USA). Finally, the pooled libraries were sequenced on a single lane of Illumina HiSeq  
376 4000 (Illumina, USA) paired-end 150 bp run.

377 Obtained reads were aligned to the human genome reference hg19 using bwa [38]. A total of  
378 51,893 bi-allelic SNVs from the Exac project are included in the targeted genomic regions. The  
379 method works only on SNVs with different genotype between donor and recipient. Under Hardy  
380 Weinberg assumption, we assessed the probability of having a different genotype for each SNV  $i$   
381 as:

$$382 \quad P(G_i^D \neq G_i^R) = \sum_{G^D=0}^2 \sum_{G^R=0}^2 F(G_i^D = G^D) * F(G_i^R = G^R) / G^D \neq G^R$$

$$383 \quad F(G_i^{D(R)} = 0) = p_i^{D(R)2}$$

$$384 \quad F(G_i^{D(R)} = 1) = 2 * p_i^{D(R)} * q_i^{D(R)}$$

$$385 \quad F(G_i^{D(R)} = 2) = q_i^{D(R)2}$$

386  
387

388 Where  $G_i^D$  and  $G_i^R$  represent the donor and recipient genotype, respectively.  $p_i^D$  and  $p_i^R$  represent  
389 the donor and recipient reference allele frequency, respectively.  $q_i^D$  and  $q_i^R$  represent the donor and  
390 recipient alternative allele frequency, respectively.

391 To avoid allele dropout due to primer annealing region, we filtered out 24,237 SNVs falling at the  
392 primer sequencing regions [35]. From the 27,656 remaining SNVs, we selected the 1,000 most  
393 common and applied the likelihood function after filtering out the reads carrying the variant at the  
394 last 20 base pairs [39].

395

### 396 **Simulated SNVs in pairs of individuals from the same and different ethnicity**

397 We used individuals from the 1,000 genomes project phase 3 representing five major populations:  
398 AFR, AMR, EAS, EUR and SAS [34]. We randomly selected two individuals and aimed to cover  
399 all possible situations; five cases where Individual1 and individual2 belong to the same population  
400 and ten cases where individual1 and individual2 belong to different populations. We extracted the  
401 1,000 SNVs described previously from Individual1 and Individual2 and then merged  $\alpha$  reads from  
402 individual1 and  $1-\alpha$  from individual2 generating a combined SNV-set. We varied  $\alpha$  from 0 to 0.5

403 in steps of 0.01 and fixed the mean depth of coverage at  $M = 5,000$ . We applied the likelihood  
404 function to assess  $\alpha$  for each combined SNV-set generated. We repeated the individual selecting  
405 process 100 times to obtain an empirical distribution for each situation.

406

#### 407 **Simulated SNVs in pairs of real siblings**

408 We performed WGS on Illumina HiSeq 2500 sequencer of 91 Qatari siblings from 27 nuclear  
409 families containing at least 2 siblings at up to 7 siblings [33]. Reads were aligned to the hg19  
410 reference genome using bwa [38]. Sequence alignment files were filtered and genotypes were  
411 called using the Genome Analysis Tool Kit best practices pipeline and variants were called using  
412 HaplotypeCaller [40,41]. We used Plink identity by state to confirm the familial relationship [42]  
413 (Fig S5). We extracted the 1,000 SNVs described previously from each sibling and merged each  
414 couple generating 100 combined SNV-sets. We applied the likelihood function to assess  $\alpha$  for each  
415 combined SNV-set generated by varying  $\alpha$  from 0 to 0.5 with a step of 0.01 while the mean depth  
416 of coverage was set at  $M = 5,000$ .

#### 417 **Donor-specific DNA fraction in real kidney recipient urine DNA**

418 We studied 32 biopsy matched urine specimens collected from 26 kidney allograft recipients who  
419 were enrolled in the IRB approved study protocol entitled “Use of urine PCR to evaluate renal  
420 allograft status” at Weill Cornell Medicine-New York Presbyterian Hospital. Kidney allograft  
421 biopsies were classified as acute rejection (n= 12), acute tubular necrosis (n=11) and normal  
422 histology (n=9) using the Banff 2017 schema [43] (Table 1). DNA was extracted from urinary  
423 cells and deep targeted DNA sequencing was performed on all samples. Briefly, 50cc of fresh  
424 urine was centrifuged at 2,000g for 30 minutes at room temperature and the urine cell pellet was  
425 harvested after removing the supernatant. After washing the urine cell pellet with 1ml PBS, the  
426 cells were lysed using 350ul of Buffer RLT from Qiagen® and DNA was isolated from the cell  
427 pellet using Allprep DNA/RNA/Protein Mini Kit from Qiagen®. Total DNA was quantified using  
428 the NanoDrop™ Spectrophotometer. DNA sequencing was performed as previously described for  
429 the pair of healthy individuals. Obtained reads were aligned to the human genome reference hg19  
430 using bwa [38]. We filtered out low quality reads using an in-house python script. We applied the  
431 likelihood function on the 1,000 SNV-set to estimate the recipient-specific DNA fraction.  
432 Nonparametric Kruskal-Wallis test was applied to assess the correlation between *observed*  $\alpha$  and

433 all the diagnosis phenotypes. Dunn's function was applied to test the pairwise association. R  
434 software was used for statistical tests and generating graphs [44].

435

### 436 **Ethnicity estimation for donor and recipient**

437 We combined the *observed*  $\alpha$  in the kidney transplant patients with a cost function to predict the  
438 genotype of both recipient ( $g_i^R$ ) and donor ( $g_i^D$ ) at each SNV  $i$ . First, we computed the expected  
439 fraction of the alternative to the total allele (reference + alternative)  $exp_i$  to all 9 possible  
440 combinations of  $g_i^R$  and  $g_i^D$  (Table 2). The observed fraction of the alternative to total alleles ( $obs_i$ )  
441 at the SNV  $i$  is defined by:

$$442 \quad obs_i = \frac{\text{Number of reads carrying the alternative allele}}{\text{Total number of reads covering the SNV } i}$$

443 Then, we used the cost function to determine  $g_i^R$  and  $g_i^D$  that minimizes the difference between the  
444 9 expected ( $exp_i$ ) and the observed ( $obs_i$ ) fraction of the alternative to total alleles:

445

$$446 \quad Loss(\alpha, g_i^R, g_i^D) = \text{Min}_{o=1}^9 (exp_{io} - obs_i)^2$$

447

448 Once  $g_i^R$  and  $g_i^D$  estimated, we performed a partial least square analysis (PLS) using 3  
449 subpopulations from the 1,000 genomes project African, east Asian and European populations  
450 using the mixOmics R package [45] and then predicted the ethnicity of donor and recipient in the  
451 real kidney transplant samples. The leave 2 out 1,000 fold cross validation showed the highest  
452 prediction accuracy = 81.6% reached when using the Yoruba in Ibadan in Nigeria, the Southern  
453 Han Chinese and the Toscani in Italia amongst the African, east Asian and European  
454 subpopulations (Fig S6). We excluded the American and the south Asian populations because  
455 using 1,000 SNVs only is too small to perform a reliable PLS on 5 populations where the highest  
456 cross validation prediction accuracy was too low on five populations: 54.8% (Fig S6).  
457 Additionally, none of the donors and recipients involved in the study belongs to the south Asian  
458 or the American populations.

459

460

461 **Acknowledgments**

462  
463 This work was supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar,  
464 a program funded by the Qatar Foundation. This work was fund, in part, by awards from the NIH  
465 to MS (NIH MERIT Award, R37AI051652), TM (K08DK087824), and Weill Cornell Medical  
466 College (Clinical and Translational Science Center Award UL1TR000457). Lastly, this work was  
467 supported, in part, by the Qatar National research Fund (National Priorities Research Program  
468 grant # NPRP12S-0227-190173).

469 **Ethics Statement**

470 Kidney transplant recipients reported herein provided written informed consent to participate in  
471 Weill Cornell Medicine IRB approved study protocol entitled “Use of urine PCR to evaluate renal  
472 allograft status” and the informed consent was obtained before collection of urine specimen and  
473 inclusion in the study protocol. The participants provided consent for storage of biospecimens and  
474 use of these specimens in future research. The clinical and research activities that we report here  
475 are consistent with the principles of the “Declaration of Istanbul on Organ Trafficking and  
476 Transplant Tourism” and the “World Medical Association Declaration of Helsinki on Ethical  
477 Principles for Medical Research Involving Human Subjects” [46,47].

478

## 479 **References**

- 480 1. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the  
481 human: report of nine cases. *J Clin Invest.* 1955;34: 327–382. doi:10.1172/JCI103085
- 482 2. Tsai M-K, Wu F-LL, Lai I-R, Lee C-Y, Hu R-H, Lee P-H. Decreased acute rejection and improved  
483 renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.  
484 *Int J Artif Organs.* 2009;32: 371–380.
- 485 3. Nankivell BJ, Kuypers DRJ. Diagnosis and prevention of chronic kidney allograft loss. *Lancet Lond*  
486 *Engl.* 2011;378: 1428–1437. doi:10.1016/S0140-6736(11)60699-5
- 487 4. Jalalzadeh M, Mousavinasab N, Peyrovi S, Ghadiani MH. The impact of acute rejection in kidney  
488 transplantation on long-term allograft and patient outcome. *Nephro-Urol Mon.* 2015;7: e24439.  
489 doi:10.5812/numonthly.24439
- 490 5. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New  
491 Zealand: relationships between rejection and graft outcome. *Am J Transplant Off J Am Soc*  
492 *Transplant Am Soc Transpl Surg.* 2007;7: 1201–1208. doi:10.1111/j.1600-6143.2007.01759.x
- 493 6. Rush D. Can protocol biopsy better inform our choices in renal transplantation? *Transplant Proc.*  
494 2009;41: S6-8. doi:10.1016/j.transproceed.2009.06.092
- 495 7. Suthanthiran M, Schwartz JE, Ding R, Abecassis M, Dadhania D, Samstein B, et al. Urinary-cell  
496 mRNA profile and acute cellular rejection in kidney allografts. *N Engl J Med.* 2013;369: 20–31.  
497 doi:10.1056/NEJMoa1215555
- 498 8. Li L, Khatri P, Sigdel TK, Tran T, Ying L, Vitalone MJ, et al. A peripheral blood diagnostic test for  
499 acute rejection in renal transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl*  
500 *Surg.* 2012;12: 2710–2718. doi:10.1111/j.1600-6143.2012.04253.x
- 501 9. Nakorchevsky A, Hewel JA, Kurian SM, Mondala TS, Campbell D, Head SR, et al. Molecular  
502 mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue  
503 biopsies. *J Am Soc Nephrol JASN.* 2010;21: 362–373. doi:10.1681/ASN.2009060628
- 504 10. Sigdel TK, Kaushal A, Gritsenko M, Norbeck AD, Qian W-J, Xiao W, et al. Shotgun proteomics  
505 identifies proteins specific for acute renal transplant rejection. *Proteomics Clin Appl.* 2010;4: 32–47.  
506 doi:10.1002/prca.200900124
- 507 11. Ling XB, Sigdel TK, Lau K, Ying L, Lau I, Schilling J, et al. Integrative urinary peptidomics in renal  
508 transplantation identifies biomarkers for acute rejection. *J Am Soc Nephrol JASN.* 2010;21: 646–653.  
509 doi:10.1681/ASN.2009080876
- 510 12. Suhre K, Schwartz JE, Sharma VK, Chen Q, Lee JR, Muthukumar T, et al. Urine Metabolite Profiles  
511 Predictive of Human Kidney Allograft Status. *J Am Soc Nephrol JASN.* 2016;27: 626–636.  
512 doi:10.1681/ASN.2015010107
- 513 13. Verma A, Muthukumar T, Yang H, Lubetzky M, Cassidy MF, Lee JR, et al. Urinary cell  
514 transcriptomics and acute rejection in human kidney allografts. *JCI Insight.* 2020;5.  
515 doi:10.1172/jci.insight.131552

- 516 14. Lo YM, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM. Presence of donor-specific DNA in  
517 plasma of kidney and liver-transplant recipients. *Lancet Lond Engl.* 1998;351: 1329–1330.
- 518 15. García Moreira V, Prieto García B, Baltar Martín JM, Ortega Suárez F, Alvarez FV. Cell-free DNA  
519 as a noninvasive acute rejection marker in renal transplantation. *Clin Chem.* 2009;55: 1958–1966.  
520 doi:10.1373/clinchem.2009.129072
- 521 16. Sigdel TK, Vitalone MJ, Tran TQ, Dai H, Hsieh S-C, Salvatierra O, et al. A rapid noninvasive assay  
522 for the detection of renal transplant injury. *Transplantation.* 2013;96: 97–101.  
523 doi:10.1097/TP.0b013e318295ee5a
- 524 17. Macher HC, Suárez-Artacho G, Guerrero JM, Gómez-Bravo MA, Álvarez-Gómez S, Bernal-Bellido  
525 C, et al. Monitoring of transplanted liver health by quantification of organ-specific genomic marker  
526 in circulating DNA from receptor. *PLoS One.* 2014;9: e113987. doi:10.1371/journal.pone.0113987
- 527 18. Snyder TM, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ  
528 transplant rejection. *Proc Natl Acad Sci U S A.* 2011;108: 6229–6234. doi:10.1073/pnas.1013924108
- 529 19. De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al. Circulating cell-free  
530 DNA enables noninvasive diagnosis of heart transplant rejection. *Sci Transl Med.* 2014;6: 241ra77.  
531 doi:10.1126/scitranslmed.3007803
- 532 20. Hidestrand M, Tomita-Mitchell A, Hidestrand PM, Oliphant A, Goetsch M, Stamm K, et al. Highly  
533 sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-  
534 specific cell-free deoxyribonucleic acid. *J Am Coll Cardiol.* 2014;63: 1224–1226.  
535 doi:10.1016/j.jacc.2013.09.029
- 536 21. Gordon PMK, Khan A, Sajid U, Chang N, Suresh V, Dimnik L, et al. An Algorithm Measuring  
537 Donor Cell-Free DNA in Plasma of Cellular and Solid Organ Transplant Recipients That Does Not  
538 Require Donor or Recipient Genotyping. *Front Cardiovasc Med.* 2016;3: 33.  
539 doi:10.3389/fcvm.2016.00033
- 540 22. Grskovic M, Hiller DJ, Eubank LA, Sninsky JJ, Christopherson C, Collins JP, et al. Validation of a  
541 Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant  
542 Recipients. *J Mol Diagn JMD.* 2016;18: 890–902. doi:10.1016/j.jmoldx.2016.07.003
- 543 23. Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, et al. Cell-Free DNA  
544 and Active Rejection in Kidney Allografts. *J Am Soc Nephrol JASN.* 2017.  
545 doi:10.1681/ASN.2016091034
- 546 24. Sharon E, Shi H, Kharbanda S, Koh W, Martin LR, Khush KK, et al. Quantification of transplant-  
547 derived circulating cell-free DNA in absence of a donor genotype. *PLoS Comput Biol.* 2017;13:  
548 e1005629. doi:10.1371/journal.pcbi.1005629
- 549 25. Zhong XY, Hahn D, Troeger C, Klemm A, Stein G, Thomson P, et al. Cell-free DNA in urine: a  
550 marker for kidney graft rejection, but not for prenatal diagnosis? *Ann N Y Acad Sci.* 2001;945: 250–  
551 257.
- 552 26. Thareja G, Yang H, Hayat S, Mueller FB, Lee JR, Lubetzky M, et al. Single nucleotide variant counts  
553 computed from RNA sequencing and cellular traffic into human kidney allografts. *Am J Transplant  
554 Off J Am Soc Transplant Am Soc Transpl Surg.* 2018;18: 2429–2442. doi:10.1111/ajt.14870



- 555 27. Cheng AP, Burnham P, Lee JR, Cheng MP, Suthanthiran M, Dadhania D, et al. A cell-free DNA  
556 metagenomic sequencing assay that integrates the host injury response to infection. *Proc Natl Acad*  
557 *Sci U S A*. 2019;116: 18738–18744. doi:10.1073/pnas.1906320116
- 558 28. Burnham P, Dadhania D, Heyang M, Chen F, Westblade LF, Suthanthiran M, et al. Urinary cell-free  
559 DNA is a versatile analyte for monitoring infections of the urinary tract. *Nat Commun*. 2018;9: 2412.  
560 doi:10.1038/s41467-018-04745-0
- 561 29. Jun G, Flickinger M, Hetrick KN, Romm JM, Doheny KF, Abecasis GR, et al. Detecting and  
562 estimating contamination of human DNA samples in sequencing and array-based genotype data. *Am*  
563 *J Hum Genet*. 2012;91: 839–848. doi:10.1016/j.ajhg.2012.09.004
- 564 30. Flickinger M, Jun G, Abecasis GR, Boehnke M, Kang HM. Correcting for Sample Contamination in  
565 Genotype Calling of DNA Sequence Data. *Am J Hum Genet*. 2015;97: 284–290.  
566 doi:10.1016/j.ajhg.2015.07.002
- 567 31. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, et al. Analysis of 6,515 exomes  
568 reveals the recent origin of most human protein-coding variants. *Nature*. 2013;493: 216–220.  
569 doi:10.1038/nature11690
- 570 32. Li X, Wu Y, Zhang L, Cao Y, Li Y, Li J, et al. Comparison of three common DNA concentration  
571 measurement methods. *Anal Biochem*. 2014;451: 18–24. doi:10.1016/j.ab.2014.01.016
- 572 33. Kumar P, Al-Shafai M, Al Muftah WA, Chalhoub N, Elsaid MF, Aleem AA, et al. Evaluation of  
573 SNP calling using single and multiple-sample calling algorithms by validation against array base  
574 genotyping and Mendelian inheritance. *BMC Res Notes*. 2014;7: 747. doi:10.1186/1756-0500-7-747
- 575 34. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al.  
576 A global reference for human genetic variation. *Nature*. 2015;526: 68–74. doi:10.1038/nature15393
- 577 35. Gray PN, Dunlop CLM, Elliott AM. Not All Next Generation Sequencing Diagnostics are Created  
578 Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection.  
579 *Cancers*. 2015;7: 1313–1332. doi:10.3390/cancers7030837
- 580 36. S O, Jf B, Pa K, Ac W, Lc R, K S. Primary acute renal failure (“acute tubular necrosis”) in the  
581 transplanted kidney: morphology and pathogenesis. In: *Medicine [Internet]*. *Medicine (Baltimore)*;  
582 May 1989 [cited 21 Sep 2020]. doi:10.1097/00005792-198905000-00005
- 583 37. Kirkpatrick S, Gelatt CD, Vecchi MP. Optimization by simulated annealing. *Science*. 1983;220: 671–  
584 680. doi:10.1126/science.220.4598.671
- 585 38. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinforma*  
586 *Oxf Engl*. 2010;26: 589–595. doi:10.1093/bioinformatics/btp698
- 587 39. CASPER: context-aware scheme for paired-end reads from high-throughput amplicon sequencing. -  
588 PubMed - NCBI. [cited 31 May 2018]. Available: <https://www.ncbi.nlm.nih.gov/pubmed/25252785>
- 589 40. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzky A, et al. The Genome  
590 Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.  
591 *Genome Res*. 2010;20: 1297–1303. doi:10.1101/gr.107524.110



- 592 41. Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, et al. Whole-genome sequencing is  
593 more powerful than whole-exome sequencing for detecting exome variants. *Proc Natl Acad Sci U S*  
594 *A*. 2015;112: 5473–5478. doi:10.1073/pnas.1418631112
- 595 42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for  
596 whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81: 559–  
597 575. doi:10.1086/519795
- 598 43. C R, N S, M CG, M H, K j H, C H, et al. A 2018 Reference Guide to the Banff Classification of Renal  
599 Allograft Pathology. In: *Transplantation* [Internet]. *Transplantation*; Nov 2018 [cited 21 Sep 2020].  
600 doi:10.1097/TP.0000000000002366
- 601 44. R: a language and environment for statistical computing. [cited 8 Nov 2018]. Available:  
602 <https://www.gbif.org/tool/81287/r-a-language-and-environment-for-statistical-computing>
- 603 45. Cao K-AL, Rohart F, Gonzalez I, Gautier SD with key contributors B, Monget FB and contributions  
604 from P, Coquery J, et al. *mixOmics: Omics Data Integration Project*. 2018. Available:  
605 <https://CRAN.R-project.org/package=mixOmics>
- 606 46. Participants in the International Summit on Transplant Tourism and Organ Trafficking Convened by  
607 The Transplantation Society and International Society of Nephrology in Istanbul T. The Declaration  
608 of Istanbul on Organ Trafficking and Transplant Tourism. *Clin J Am Soc Nephrol CJASN*. 2008;3:  
609 1227. doi:10.2215/CJN.03320708
- 610 47. World Medical Association Declaration of Helsinki: ethical principles for medical research involving  
611 human subjects. In: *JAMA* [Internet]. *JAMA*; 27 Nov 2013 [cited 21 Sep 2020].  
612 doi:10.1001/jama.2013.281053
- 613 48. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative  
614 genomics viewer. *Nat Biotechnol*. 2011;29: 24–26. doi:10.1038/nbt.1754
- 615